Lyra Therapeutics (LYRA) Free Cash Flow (2019 - 2025)
Lyra Therapeutics (LYRA) recorded quarterly Free Cash Flow of -$6.2 million in Q4 2025, up 16.29% on a QoQ basis from -$7.4 million in Q3 2025, and up 45.44% YoY from -$4.2 million in Q4 2024.
Lyra Therapeutics (LYRA) Free Cash Flow (2019 - 2025) Analysis & Trends
Lyra Therapeutics (LYRA) has reported Free Cash Flow for 7 consecutive years, with -$6.2 million the latest figure, recorded in Q4 2025.
- Free Cash Flow for Q4 2025 came in at -$6.2 million, up 45.44% year-over-year; the trailing twelve-month figure through Dec 2025 was -$29.0 million (up 59.98% YoY), and the FY2025 annual result was -$29.0 million, up 59.95% from the prior year.
- Free Cash Flow for Q4 2025 stood at -$6.2 million, up from -$7.4 million in the prior quarter.
- The five-year high for Free Cash Flow was $2.8 million in Q2 2021, with the low at -$24.6 million in Q1 2024.
- A 5-year average of -$11.7 million and a median of -$11.1 million in 2022 frame the typical range for Free Cash Flow.
- Across the five-year window, Free Cash Flow soared 136.75% in 2021 and tumbled 404.17% in 2022, its largest moves.
- Lyra Therapeutics' Free Cash Flow stood at -$10.3 million in 2021, then fell by 18.5% to -$12.2 million in 2022, then sank by 59.29% to -$19.4 million in 2023, then jumped by 41.85% to -$11.3 million in 2024, then soared by 45.44% to -$6.2 million in 2025.
- The last three Free Cash Flow figures came in at -$6.2 million (Q4 2025), -$7.4 million (Q3 2025), and -$6.6 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -563.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 437.80 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 292.04 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 433.84 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -95.09 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 477.44 Mn |
| 10 | Lyra Therapeutics | 70,995.28 | 70,995.28 | - | -6.12 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -6.16 Mn |
| Dec 31, 2025 | -6.16 Mn |
| Sep 30, 2025 | -7.36 Mn |
| Sep 30, 2025 | -7.36 Mn |
| Jun 30, 2025 | -6.59 Mn |
| Jun 30, 2025 | -6.59 Mn |
| Mar 31, 2025 | -8.84 Mn |
| Mar 31, 2025 | -8.84 Mn |
| Dec 31, 2024 | -11.29 Mn |
| Dec 31, 2024 | -11.29 Mn |
| Sep 30, 2024 | -18.56 Mn |
| Sep 30, 2024 | -18.56 Mn |
| Jun 30, 2024 | -17.90 Mn |
| Jun 30, 2024 | -17.90 Mn |
| Mar 31, 2024 | -24.60 Mn |
| Mar 31, 2024 | -24.60 Mn |
| Dec 31, 2023 | -19.42 Mn |
| Dec 31, 2023 | -19.42 Mn |
| Sep 30, 2023 | -14.26 Mn |
| Sep 30, 2023 | -14.26 Mn |